Financial Performance - Cash and cash equivalents as of September 30, 2024, were $157.0 million, expected to fund operations into 2027[2] - Net loss for Q3 2024 was $29.5 million, or $0.89 per share, compared to a net loss of $20.1 million, or $12.36 per share, in Q3 2023[5] - Total operating expenses for Q3 2024 were $31.5 million, compared to $20.3 million in Q3 2023, reflecting a 55% increase[5] Research and Development - R&D expenses for Q3 2024 were $23.4 million, up from $17.2 million in Q3 2023, representing a 36.5% increase[3] - Interim data from LX2006 showed a 35% increase in frataxin protein expression and a 279% increase in frataxin positive area post-treatment[3] - Initial clinical data for LX2020 HEROIC-PKP2 Phase 1/2 trial expected in late Q1 / early Q2 2025[2] General and Administrative Expenses - G&A expenses for Q3 2024 were $8.1 million, compared to $3.0 million in Q3 2023, indicating a 170% increase[3] Clinical Trials and Designations - Enrollment completed for LX2006 SUNRISE-FA Phase 1/2 trial, with a total of 16 participants dosed to date[2] - FDA granted RMAT designation for LX2006 for the treatment of Friedreich ataxia cardiomyopathy, allowing for expedited development[2] Assets - Total assets as of September 30, 2024, were $173.9 million, up from $139.8 million as of December 31, 2023[7]
Lexeo Therapeutics(LXEO) - 2024 Q3 - Quarterly Results